Low-intensity focused ultrasound for cocaine use disorder: High resolution targeting of the human insula
Low-intensity focused ultrasound for cocaine use disorder: High resolution targeting of the human insula
批准号:
10669693
负责人:
NASSIMA AIT-DAOUD
金额:
$59.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-01 至 2024-07-31
关键词:
AbstinenceAddictive BehaviorAdoptionAffectAnatomyAnimal ModelAnteriorAreaBehavioralBrainBrain regionCessation of lifeChronicClinicalCocaineCocaine DependenceCocaine use disorderCuesDataDecision MakingDiseaseDorsalDoseEmotionalFDA approvedFocused UltrasoundFutureGoalsHumanIndividualInsula of ReilInterventionLateralLesionLongevityMagnetic Resonance ImagingMaintenanceMeasuresMethodsModelingNeurologicNeurosurgical ProceduresPatient Self-ReportPatientsPharmaceutical PreparationsPharmacotherapyPhasePhysiologicalPopulationPredispositionRelapseResolutionSafetySensorySocietiesSpottingsStimulusSubstance Use DisorderTechniquesTechnologyTemporal LobeTherapeuticTherapeutic EffectTreatment EfficacyUltrasonic TherapyUnited States Food and Drug AdministrationVisceraladdictionblood oxygen level dependentbrain dysfunctioncatalystclinical effectcocaine cravingcocaine cuecocaine exposurecocaine seekingcocaine usecostcraniumcravingcue reactivitydirected attentionexperienceimprovedinnovationmillimetermultimodal dataneurobehavioralneuroregulationnoninvasive brain stimulationnovel therapeutic interventionrepairedresponsesafety assessmentsafety testingsmoking cessationstemtransmission processultrasound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Cocaine use disorder (CUD) is a chronic relapsing disorder with significant burden to society costing more than
$85 billion per year globally and there is no US Food and Drug Administration-approved intervention. There is a
critical need to develop effective new treatment strategies. One rapidly emerging potential therapeutic is
neuromodulation using low-intensity focused ultrasound (LIFU). The enormous potential of LIFU stems from the
ability to focus ultrasound through the intact skull to a millimeter-sized focal spot size anywhere in the brain. This
makes it a powerful alternative to both invasive neurosurgical procedures and other noninvasive brain stimulation
techniques that have limited spatial resolution and can only reach superficial areas of the brain. One promising
target to treat cocaine use disorder (CUD) is the dorsal anterior insular cortex (dAI). Unfortunately, the dAI lies
deep within the lateral sulcus covered by the overlying opercula of the temporal lobe and is not accessible with
conventional noninvasive neuromodulatory techniques. As such, LIFU provides a potentially transformative
methods to non-invasively modulate the dAI to reduce cocaine craving and addiction. The dAI is a critical brain
region which is activated in the response to drug cue exposure and its extent of activation is positively correlated
with self-reported craving in human studies. In small animal models, reversible inactivation of dorsal anterior
insula reduces cocaine seeking, decreases relapse after voluntary abstinence and decreases cue-induced and
context-induced reinstatement of cocaine seeking. Remarkably, humans with damage to the insula were able to
stop smoking easily and without experiencing cravings or relapse. In addition, the dAI is part of the salience
network (SN). The SN is implicated in the direction of attention toward important stimuli and integration of top-
down appraisal and bottom-up visceral and sensory information. Models posit the dAI first assesses the
emotional value of incoming stimuli before transmitting the information to other nodes to plan and initiate future
goal directed actions. In addiction this network is dysfunctional leading to a disproportionate saliency and
sensitivity to drug related cues that biases decision making to use and ultimately abuse.
To advance LIFU as a potential therapeutic for the treatment of CUD, in the UG3 phase of this proposal we will
first test the safety and tolerability of the intervention and examine how selective inhibition of dAI reduces its
activity to affect cue-induced craving. Develop. Upon successful completion of the UG3 phase, the UH3 phase
will build upon these findings by examining the effect of dose and the duration of effect as well as how LIFU to
dAI affects whole-brain network dynamics as how this affects craving for cocaine. The application of this
information will provide a fundamental break-through in understanding how ultrasound energy can be rationally
deployed to produce predictable clinical effects and act as a catalyst for the widespread clinical adoption of this
technology for the treatment of CUD as well as other forms of substance use disorder.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
1/2-Pharmacogenetic Treatments for Alcoholism
-
批准号:8273389
-
项目类别:
-
资助金额:$54.37万
-
财政年份:2012
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
1/2-Pharmacogenetic Treatments for Alcoholism
-
批准号:8460484
-
项目类别:
-
资助金额:$53.16万
-
财政年份:2012
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Pharmacotherapy for Alcohol and Co-morbid Disorders
-
批准号:8318743
-
项目类别:
-
资助金额:$88.25万
-
财政年份:2010
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Pharmacotherapy for Alcohol and Co-morbid Disorders
-
批准号:8520114
-
项目类别:
-
资助金额:$80.7万
-
财政年份:2010
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Pharmacotherapy for Alcohol and Co-morbid Disorders
-
批准号:8139054
-
项目类别:
-
资助金额:$90.06万
-
财政年份:2010
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Pharmacotherapy for Alcohol and Co-morbid Disorders
-
批准号:7949511
-
项目类别:
-
资助金额:$96.42万
-
财政年份:2010
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Medication Treatments for Stimulant Dependence
-
批准号:8013349
-
项目类别:
-
资助金额:$58.5万
-
财政年份:2007
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Medication Treatments for Stimulant Dependence
-
批准号:7313772
-
项目类别:
-
资助金额:$60.57万
-
财政年份:2007
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Medication Treatments for Stimulant Dependence
-
批准号:8210949
-
项目类别:
-
资助金额:$27.01万
-
财政年份:2007
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Medication Treatments for Stimulant Dependence
-
批准号:7751305
-
项目类别:
-
资助金额:$59.37万
-
财政年份:2007
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
New Medication Treatments for Stimulant Dependence
-
批准号:7491784
-
项目类别:
-
资助金额:$58.98万
-
财政年份:2007
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
DO GENES & BRAIN ACTIVITY PREDICT ALCOHOL RISK?
-
批准号:6231219
-
项目类别:
-
资助金额:$16.29万
-
财政年份:2001
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
DO GENES & BRAIN ACTIVITY PREDICT ALCOHOL RISK?
-
批准号:6797406
-
项目类别:
-
资助金额:$1.63万
-
财政年份:2001
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
DO GENES & BRAIN ACTIVITY PREDICT ALCOHOL RISK?
-
批准号:7054611
-
项目类别:
-
资助金额:$15.25万
-
财政年份:2001
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
DO GENES & BRAIN ACTIVITY PREDICT ALCOHOL RISK?
-
批准号:6945944
-
项目类别:
-
资助金额:$17.27万
-
财政年份:2001
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
DO GENES & BRAIN ACTIVITY PREDICT ALCOHOL RISK?
-
批准号:6652478
-
项目类别:
-
资助金额:$16.49万
-
财政年份:2001
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
DO GENES & BRAIN ACTIVITY PREDICT ALCOHOL RISK?
-
批准号:6532359
-
项目类别:
-
资助金额:$16.12万
-
财政年份:2001
-
负责人:NASSIMA AIT-DAOUD
-
依托单位:
海外基金